ClickCease

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.

Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: 10.1080/02791072.2019.1587556. Epub 2019 Mar 27. PMID: 30917760. Highlights: Our findings suggest […]

Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.

Bipolar-Depressive-Episoide

Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing, and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-7. doi: 10.1017/S1461145713000485. Epub 2013 May 20. PMID: 23683309. Highlights: According to patients’ reports, VLDS [very low dose sublingual] ketamine produced rapid, clear, and sustained effects, improving […]

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

Anand, A et al. (2023).  Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.  N Engl J Med 2023;388:2315-25. DOI: 10.1056/NEJMoa2302399  Highlights: A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response. Patients with treatment-resistant major depression without psychosis were recruited and assigned in […]

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression.

Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W. (2020). Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology, 45(6), 975–981.  Highlights: There was a significant improvement in MDD symptoms following a single-dose intravenous ketamine. Following a 40-minute infusion of ketamine at a dose of 0.5mg/kg, patients […]

Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.

Chen, M. H., Wu, H. J., Li, C. T., Lin, W. C., Tsai, S. J., Hong, C. J., Tu, P. C., Bai, Y. M., Mao, W. C., & Su, T. P. (2021). Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. Human Psychopharmacology: Clinical and Experimental, […]

Treatment resistant depression at a glance with traditional, first line antidepressant treatments, as well as a review of the evidence behind esketamine, psilocybin and pramipexole.

Kverno KS, Mangano E. Treatment-Resistant Depression: Approaches to Treatment. J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11. doi: 10.3928/02793695-20210816-01. Epub 2021 Sep 1. PMID: 34459676. Highlights: Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant […]

Ketamine and the Future of Rapid-Acting Antidepressants.

Lace M. Riggs and Todd D. Gould.  Ketamine and the Future of Rapid-Acting Antidepressants.  Annual Review of Clinical Psychology 2021 17:1, 207-231   Highlights: The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression […]

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.

Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology (Berl). 2021 Apr;238(4):1157-1169. doi: 10.1007/s00213-021-05762-6. Epub 2021 Jan 22. PMID: 33483802; PMCID: PMC7969576.   Highlights: In this open-label, proof-of-principle study, adults […]

Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.

Highlights: The rapid and robust antidepressant effects of single-dose ketamine in patients with TRD suggest that ketamine is a promising candidate for an effective therapy in patients who do not respond to conventional treatment. Our findings showed that a single administration of ketamine reduces depressive symptoms and that the initial antidepressant effects of the drug […]

Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.

Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety. 2020 Mar;37(3):224-233. doi: 10.1002/da.22975. Epub 2019 Nov 16. PMID: 31733088. Highlights: A single dose of IV ketamine produced effective and rapid reductions in suicidal ideation in as little as 90 minutes. 88% […]